Integrated epigenomics identifies <i>BMP4</i> as a modulator of cisplatin sensitivity in gastric cancer

Abstract

BMP4 epigenetic and expression status may represent promising biomarkers for GC cisplatin resistance. Targeting BMP4 may sensitise GC cells to cisplatin. Oxaliplatin, a clinically acceptable cisplatin alternative, may represent a potential therapeutic option for BMP4-positive GCs.